How Long Does Buprenorphine Stay in Your System?

Buprenorphine has a long elimination half-life, averaging around 25 hours but varying widely from person to person, with reported averages spanning roughly 3 to 44 hours depending on the route of administration and individual metabolism. That means the drug can take anywhere from a few days to over a week to fully clear from your bloodstream after a single dose, and considerably longer if you have been taking it regularly. Detection windows on drug tests stretch even further, especially for urine and hair testing, which pick up metabolites that linger after the parent drug is gone. The answer depends heavily on what formulation you are taking, how healthy your liver is, and what kind of test you are facing.

How Your Body Breaks Down Buprenorphine

Buprenorphine is processed almost entirely by the liver. The primary route is a specific liver enzyme called CYP3A4, which accounts for roughly 65% of the drug’s breakdown and converts buprenorphine into its main metabolite, norbuprenorphine.¹ Early laboratory work confirmed that among the major drug-metabolizing enzymes, CYP3A4 is the only one capable of performing this conversion.² This metabolite, norbuprenorphine, actually clears from the body faster than buprenorphine itself, but with repeated dosing its concentration can build up and exceed that of the parent drug.³ That accumulation matters for drug testing, because most lab assays measure both buprenorphine and norbuprenorphine.

Because the liver does nearly all the work, the speed of elimination hinges on liver function far more than kidney function. This is an unusual trait among opioids and has real practical consequences for people with organ disease, which we will get to shortly.

The Half-Life Range and What It Means for Clearance

A controlled study measuring intravenous buprenorphine across several dose levels found a mean half-life of about 25 hours.⁴ But that average hides enormous person-to-person variability. A clinical pharmacokinetics review reported that mean half-life values across different studies ranged from 3 to 44 hours.⁵ That is more than a tenfold spread, which is unusual for a widely used medication and partly explains why some people seem to metabolize their dose quickly while others hold onto it much longer.

A commonly used rule of thumb is that a drug is essentially gone after about five half-lives. Using the 25-hour average, that puts full clearance from blood at roughly five to six days after a single dose. But for someone on the shorter end (say, a half-life closer to 12 hours), it could be about two to three days. For someone on the longer end, closer to 40 hours, clearance could stretch past eight days. And if you have been taking buprenorphine daily for weeks or months, steady-state accumulation means it takes even longer for blood levels to reach zero after your last dose.

Detection Windows by Test Type

Standard workplace opioid immunoassays do not detect buprenorphine at all. Because its chemical structure differs from drugs like morphine, heroin, and oxycodone, a routine urine screen will not flag it. Detecting buprenorphine requires a test specifically designed for it, which looks for the drug and its norbuprenorphine metabolite. Clinics prescribing buprenorphine for opioid use disorder routinely run this specific test to confirm patients are actually taking their medication rather than diverting it.

Urine

Urine is the most common sample type used in clinical monitoring. Norbuprenorphine concentrations in urine are used alongside buprenorphine levels to assess whether someone is taking their medication as prescribed. Researchers studying these urinary ratios found that the ratio of norbuprenorphine to buprenorphine could distinguish distinct patient populations, and abnormally low ratios flagged specimens that may have been tampered with.⁶ In practice, buprenorphine is generally detectable in urine for several days after a single dose and can remain positive for well over a week in people who have been taking it regularly, because the metabolites continue washing out even after the drug itself has left the bloodstream.

Saliva

Oral fluid testing offers a narrower detection window. After a single 1 mg sublingual dose, buprenorphine concentrations in saliva have been measured in the range of 1 to 10 micrograms per milliliter, persisting between roughly 5 and 20 hours after the dose.⁷ That makes saliva a useful tool for confirming very recent use but a poor choice for catching buprenorphine taken days earlier.

Hair

Hair testing operates on a completely different timescale. Because drugs incorporate into growing hair, a hair sample can reveal buprenorphine exposure going back months. Researchers have used segmental hair analysis to track buprenorphine intake over time in patients on maintenance therapy, which allows clinicians to see patterns of dosing compliance across weeks or months rather than just the past few days.⁸ Hair testing is rarely used in clinical settings but can show up in forensic or legal situations.

Blood

Blood (plasma) testing is mostly reserved for research and pharmacokinetic studies. Its detection window roughly mirrors the drug’s elimination profile, so a few days for a single dose and potentially over a week for someone at steady state. In practice, you are unlikely to encounter a blood-based buprenorphine test outside of a clinical trial.

How the Formulation Changes the Timeline

Buprenorphine comes in several formulations, and the delivery method dramatically affects how long the drug stays active and detectable in your body. This is one of the biggest sources of confusion, because two people “on buprenorphine” may be experiencing completely different pharmacokinetic profiles.

Sublingual Tablets and Film

The most common formulations are tablets or films placed under the tongue. Absorption through the mouth lining is rapid, with peak blood concentrations arriving within about 45 minutes to an hour.^{9 10} From there, the drug follows the standard elimination curve discussed above. Because these are taken daily (or sometimes twice daily), people on sublingual buprenorphine maintain a steady state. After stopping, clearance follows the half-life math: expect measurable blood levels for roughly a week, with urine positivity potentially lasting longer.

Transdermal Patches

Buprenorphine patches, used mainly for chronic pain rather than addiction treatment, deliver the drug slowly through the skin. Steady-state plasma concentrations are reached within about 48 hours of applying the first patch, and once-weekly patch changes provide consistent drug levels.¹¹ After you remove the last patch, there is still a reservoir of drug in the skin that continues to release into the bloodstream for some time, making the effective elimination period somewhat longer than with sublingual dosing.

Extended-Release Injections

Monthly depot injections represent the longest-acting formulations. These are designed to slowly release buprenorphine from a subcutaneous deposit over four weeks or more. Pharmacokinetic modeling shows that after discontinuing these injections, blood levels decrease slowly and remain above clinically relevant concentrations for an extended period.¹² A bioavailability study of the monthly injection confirmed that mean plasma concentrations stayed at or above about 2 nanograms per milliliter, a therapeutic target, for 28 days.¹³ For someone coming off a depot injection, it can take weeks for the drug to fully leave the system, and even a two-week delay in getting the next shot was not predicted to meaningfully lower drug levels.¹²

Liver Disease Raises Drug Levels Substantially

Because buprenorphine is almost entirely processed in the liver, impaired liver function can significantly increase how much drug stays in your system and for how long. A pharmacokinetic study comparing people with varying degrees of liver disease to healthy volunteers found that those with severe liver impairment had total buprenorphine exposure roughly 2.8 times higher than normal, with peak concentrations about 1.7 times higher.¹⁴ People with mild liver impairment or hepatitis C infection without significant liver damage generally stayed within about twofold of healthy subjects, which is a less dramatic difference.

The same study found that naloxone, the opioid-blocking agent combined with buprenorphine in many formulations, was affected even more dramatically. In severe liver disease, naloxone exposure skyrocketed to over 14 times normal.¹⁴ This has real clinical consequences: higher naloxone levels can potentially interfere with buprenorphine’s therapeutic effect and provoke withdrawal symptoms, while simultaneously higher buprenorphine levels increase the risk of excessive sedation. Prescribers generally use lower doses or buprenorphine-only formulations for patients with moderate to severe liver disease.

Why Kidney Disease Barely Matters

This is one of the more unusual aspects of buprenorphine’s pharmacology, and good news for people on dialysis or with kidney problems. Because the drug is eliminated primarily through the liver rather than the kidneys, kidney impairment has almost no effect on how long buprenorphine stays in your system. A study comparing patients with renal impairment to healthy controls found no meaningful differences in elimination half-life or clearance between the two groups.¹⁵ Hemodialysis itself does not remove buprenorphine from the blood, which means the drug’s analgesic or therapeutic effects remain stable through dialysis sessions.¹⁶ A clinical review went so far as to note that buprenorphine can be given at normal doses in patients with kidney dysfunction, with no dose reduction needed.¹⁷

This sets buprenorphine apart from many other opioids, which are at least partially cleared through the kidneys and can accumulate dangerously in patients with renal failure. It is one reason buprenorphine is sometimes preferred for pain management in patients with chronic kidney disease.

Drug Interactions That Speed Up or Slow Down Clearance

Since CYP3A4 is the main enzyme responsible for breaking down buprenorphine, drugs that inhibit or ramp up that enzyme can change how fast buprenorphine leaves your body. The practical impact, though, turns out to be surprisingly modest. Pharmacokinetic modeling of the extended-release injection with strong CYP3A4 inhibitors predicted that buprenorphine exposure would increase by about 33% to 44%, and a strong inducer like rifampicin would decrease exposure by about 28%.¹⁸ A separate modeling study using a different extended-release formulation came to similar conclusions: a strong inhibitor increased exposure by about 35%, and a strong inducer decreased it by about 26%, both small enough that researchers concluded no dose adjustment was needed.¹⁹

Common CYP3A4 inhibitors include certain antifungals and some HIV medications. Common inducers include the antibiotic rifampicin and certain anti-seizure drugs. While these interactions do not typically warrant dose changes for buprenorphine, they are worth flagging to your prescriber, especially if you are adding or removing one of these medications mid-treatment. The interaction may not change your dose, but it can shift how quickly the drug clears, which could affect how you feel between doses.

Age, Body Weight, and Sex

Individual characteristics also play a role. A pharmacokinetic study in children undergoing surgery found that age affected both clearance and the central volume of distribution, female sex was associated with lower transfer of drug between body compartments, and body mass index modified both clearance and compartment volumes.²⁰ These are not surprising findings: most drugs are affected by body size, organ maturity, and hormonal differences. For adults, the practical takeaway is that a larger person or someone with more body fat may distribute buprenorphine into a bigger volume, potentially extending how long trace amounts remain detectable, while a smaller or leaner person may clear it somewhat faster.

Older adults also tend to have slower hepatic metabolism, which can extend the effective duration. Clinical experience suggests that elderly patients on buprenorphine patches or sublingual formulations sometimes need lower doses to achieve the same steady-state concentration as younger adults, though formal dose adjustment guidelines based purely on age remain limited.

What Happens When Blood Levels Start to Fall

One of the reasons buprenorphine’s elimination timeline matters so much is that withdrawal symptoms are directly tied to falling drug levels. Research tracking patients during dose induction, maintenance, and withdrawal from sublingual buprenorphine found that withdrawal scores rose as plasma concentrations dropped.²¹ A neuroimaging study added detail: as buprenorphine left the bloodstream, opioid receptors in the brain became progressively more available, and that availability tracked closely with the emergence of withdrawal symptoms and the loss of blockade against other opioids.²²

For people on daily sublingual buprenorphine, this means that missing a dose or two may not immediately provoke withdrawal, because the drug’s long half-life keeps concentrations in a functional range for a while. People on monthly injections have even more of a buffer, as noted earlier, since blood levels decline slowly. But the flip side is also true: when someone tapers off buprenorphine entirely, the slow decline means withdrawal symptoms can be mild but drawn out over days to weeks, rather than arriving all at once. This protracted withdrawal timeline is something many patients find frustrating compared to the sharper but shorter withdrawals associated with shorter-acting opioids.

Buprenorphine and the Enzyme It Inhibits

An interesting wrinkle in buprenorphine’s metabolism is that the drug itself can interfere with the enzyme responsible for breaking it down. Laboratory research has shown that buprenorphine effectively inhibits CYP3A4, the very enzyme that metabolizes it, as well as another enzyme called CYP2D6.²³ In theory, this self-inhibition could slow the drug’s own clearance at higher concentrations, creating a nonlinear elimination pattern where larger doses take proportionally longer to clear. It also raises the possibility that buprenorphine could affect the metabolism of other drugs processed by CYP2D6 or CYP3A4, including some antidepressants and antiarrhythmics. Whether this enzyme inhibition matters at the concentrations achieved in clinical use is still debated, but it is another factor that could contribute to the wide variability in half-life values seen across studies.